LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

Home・Aandelen Lijst・Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals Inc

Gesloten

12.38 -0.56

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

12.01

Max

12.73

Belangrijke statistieken
By Trading Economics
Inkomsten	-1.4M -14M
EPS	-0.15
Werknemers	37
EBITDA	-2.7M -15M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+144.39% upside

Dividenden
By Dow Jones
Volgende Winsten	6 aug 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-241M 1.1B
Vorige openingsprijs	12.94
Vorige sluitingsprijs	12.38

Corvus Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

28 mei 2026, 22:47 UTC

Winsten

Costco 3Q Sales Rise as Value Offerings Draw Pressured Consumers -- Update

28 mei 2026, 20:45 UTC

Winsten

Costco 3Q Profit Rises as Value Offerings Draw Pressured Consumers

28 mei 2026, 23:43 UTC

Marktinformatie

Nikkei May Rise on Hopes for U.S.-Iran Peace Deal -- Market Talk

28 mei 2026, 23:39 UTC

Marktinformatie

Gold Edges Lower as Traders Assess Potential U.S.-Iran Deal -- Market Talk

28 mei 2026, 23:31 UTC

Marktinformatie

KMD Could Realize Value From Selling Either Oboz or Rip Curl -- Market Talk

28 mei 2026, 23:17 UTC

Marktinformatie

Mainfreight Steering Its Way Out of Tough Period -- Market Talk

28 mei 2026, 23:02 UTC

Marktinformatie

Costco Has Started Submitting Tariff Refund Claims -- Market Talk

28 mei 2026, 22:41 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

28 mei 2026, 22:41 UTC

Marktinformatie

MongoDB Still Getting More Growth From Established Customers Than AI -- Market Talk

28 mei 2026, 22:37 UTC

Marktinformatie

Acquisities, Fusies, Overnames

M&A-Related Insurance Payments In North America Rise -- Market Talk

28 mei 2026, 22:04 UTC

Acquisities, Fusies, Overnames

CN: Surface Transportation Board Was Right to Freeze the UP-NS Merger and Demand More Info

28 mei 2026, 22:04 UTC

Acquisities, Fusies, Overnames

CN: This Confirms What CN and Many Stakeholders Have Said All Along, UP and NS Still Have Not Submitted a Credible Case to Support Their Proposed Merger >CNI

28 mei 2026, 21:12 UTC

Winsten

Acquisities, Fusies, Overnames

Synopsys Was the Worst S&P 500 Stock Thursday Despite Earnings Beat With AI and Merger in Focus -- Barrons.com

28 mei 2026, 21:00 UTC

Winsten

Dell Stock Soars on Blowout Earnings. The Outlook Bests Analysts by $20 Billion. -- Barrons.com

28 mei 2026, 20:57 UTC

Winsten

Dell Stock Soars on Blowout Earnings -- Barrons.com

28 mei 2026, 20:55 UTC

Winsten

Costco Wholesale Sees a Mixed Quarter, Misses Earnings Estimates -- Barrons.com

28 mei 2026, 20:50 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

28 mei 2026, 20:50 UTC

Marktinformatie

Financial Services Roundup: Market Talk

28 mei 2026, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

28 mei 2026, 20:48 UTC

Populaire aandelen

Stocks to Watch Recap: Snowflake, Union Pacific, Hormel Foods -- WSJ

28 mei 2026, 20:34 UTC

Winsten

One of the S&P 500's Highest Dividends Looks Even Better Now -- Barrons.com

28 mei 2026, 20:31 UTC

Winsten

Li and XPeng Both Miss Earnings Estimates. One Chinese EV Maker's Stock Is Rising. -- Barrons.com

28 mei 2026, 20:28 UTC

Winsten

Best Buy's 5% Dividend Yield Looks Even Better After Earnings -- Barrons.com

28 mei 2026, 20:26 UTC

Winsten

Dell Stock Soars on Blowout Earnings -- Barrons.com

28 mei 2026, 20:20 UTC

Winsten

Costco 3Q Membership Fees $1.37B

28 mei 2026, 20:20 UTC

Winsten

Costco 3Q Net Sales $69.15B

28 mei 2026, 20:19 UTC

Winsten

Costco 3Q Adj Same-Store Sales, Which Excludes Impacts From Gas Prices and Foreign Exchange, Rose 6.6% >COST

28 mei 2026, 20:19 UTC

Winsten

Costco 3Q Adjusted Digitally-Enabled Sales Rose 20.8% >COST

28 mei 2026, 20:17 UTC

Winsten

Costco 3Q Digitally-Enabled Sales Rose 21.5% >COST

28 mei 2026, 20:17 UTC

Winsten

Costco 3Q Same-Store Sales Up 9.8% >COST

Peer Vergelijking

Prijswijziging

Corvus Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

144.39% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 31.6 USD 144.39%

Hoogste 40 USD

Laagste 27 USD

Gebaseerd op 5 Wall Street-analisten die 12-maands prijsdoelen bieden voor Corvus Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

5 ratings

Buy

Hold

Sell

Gebaseerd op 5 analisten die aandelenratings hebben gegeven aan Corvus Pharmaceuticals Inc - Dist in de afgelopen 3 maanden.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.